Venus remedies jump over 14% to 8 weeks high on the FDA approval for anti-mi-robian resistance therapy | Einsmark news

Shares of Venus Remedies, one of the largest manufacturers of Meropenem antibiotics and an emerging player in AMR medicine in India, rose 14.3% in Thursday’s trade session, April 17 to reach an 8-week peak of £ 356.65. This rally has come after the company, in an exchange filing today, announced that its investigative product, VRP-034, has received the designation of qualified infectious diseases (QIDP) by the United States Food and Drug Administration (US FDA) for the treatment of bloodstream infections caused by Polymyxin B (PMB). VRP-034 was developed by Venus Medicine Research Center (VMRC), the R&D section of Venus drugs, VRP-034, a new supramolecionic (SMC) formulation of polymyxin B-sulfate, which is uniquely designed to address the nephrotoxic effects associated with conventional polymyxin b-therapy. The QIDP direction, granted under the generating antibiotic incentives Act now (GAIN), offers VRP-034 with significant regulatory benefits, including priority review, suitability for rapid designation, and an additional five years of exclusivity in the United States approval in the United States. “Receipt of QIDP direction for VRP-034 is an important milestone in our efforts to combat antimicrobial resistance,” said Saransh Chaudhary, CEO, Venus Medicine Research Center. Share price trajectory The company’s shares lost 27% of their value between August 2024 and March 2025. However, the share has so far jumped back this month, with 12%, with most of the profits coming in the trade session today. At current levels, the share trades 47.5% below its £ 639 per share, which was achieved in August 2021. For context, there was a one-way rally between March 2020 and July 2024, delivering a massive return of 2.022% to shareholders. According to the company’s shareholding, the general public shareholders had the majority stake, with 56.9% at the end of the December 2024 term. Promoters had 41.8%, while the remaining 1.3% were held by foreign institutional investors (FIIs). Disclaimer: The views and recommendations given in this article are those of individual analysts. This does not represent the views of coin. We advise investors to check with certified experts before making investment decisions. First published: 17 Apr 2025, 02:09 IST